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The consensus algorithm for the medical management of type 2 diabetes was published in
August 2006 with the expectation that it would be updated, based on the availability of new
interventions and new evidence to establish their clinical role. The authors continue to endorse
the principles used to develop the algorithm and its major features. We are sensitive to the risks
of changing the algorithm cavalierly or too frequently, without compelling new information. An
updatetotheconsensusalgorithmpublishedinJanuary2008speciﬁcallyaddressedsafetyissues
surrounding the thiazolidinediones. In this revision, we focus on the new classes of medications
that now have more clinical data and experience.
Diabetes Care 32:193–203,
T
he epidemic of type 2 diabetes and
the recognition that achieving spe-
ciﬁcglycemicgoalscansubstantially
reduce morbidity have made the effective
treatment of hyperglycemia a top priority
(1–3). While the management of hyper-
glycemia, the hallmark metabolic abnor-
malityassociatedwithtype2diabetes,has
historicallytakencenterstageinthetreat-
ment of diabetes, therapies directed at
other coincident features, such as dyslip-
idemia, hypertension, hypercoagulabil-
ity, obesity, and insulin resistance, have
also been a major focus of research and
therapy. Maintaining glycemic levels as
close to the nondiabetic range as possible
hasbeendemonstratedtohaveapowerful
beneﬁcial effect on diabetes-speciﬁc mi-
crovascular complications, including ret-
inopathy, nephropathy, and neuropathy,
in the setting of type 1 diabetes (4,5); in
type 2 diabetes, more intensive treatment
strategies have likewise been demon-
strated to reduce microvascular compli-
cations (6–8). Intensive glycemic
management resulting in lower A1C lev-
els has also been shown to have a beneﬁ-
cial effect on cardiovascular disease
(CVD) complications in type 1 diabetes
(9,10); however, current studies have
failed to demonstrate a beneﬁcial effect of
intensivediabetestherapyonCVDintype
2 diabetes (11–13).
The development of new classes of
blood glucose–lowering medications to
supplement the older therapies, such as
lifestyle-directed interventions, insulin,
sulfonylureas, and metformin, has in-
creased the number of treatment options
available for type 2 diabetes. Whether
used alone or in combination with other
blood glucose–lowering interventions,
the increased number of choices available
to practitioners and patients has height-
ened uncertainty regarding the most
appropriate means of treating this wide-
spreaddisease(14).Althoughnumerousre-
viewsonthemanagementoftype2diabetes
have been published in recent years (15–
17), practitioners are often left without a
clear pathway of therapy to follow. We de-
veloped the following consensus approach
to the management of hyperglycemia in the
nonpregnantadulttohelpguidehealthcare
providers in choosing the most appropriate
interventions for their patients with type 2
diabetes.
Process
The guidelines and algorithm that follow
are derived from two sources. One source
is the clinical trials that address the effec-
tiveness and safety of the different modal-
ities of therapy. Here, the writing group
reviewed a wide variety of studies related
to the use of drugs as monotherapy or in
combination to lower glycemia. Unfortu-
nately, the paucity of high-quality evi-
dence in the form of well-controlled
clinical trials that directly compare differ-
entdiabetestreatmentregimensremainsa
major impediment to recommending one
classofdrugs,oraparticularcombination
of therapies, over another.
Thesecondsourceofmaterialthatin-
formedourrecommendationswasclinical
judgement, that is, our collective knowl-
edge and clinical experience, which takes
intoaccountbeneﬁts,risks,andcostsinthe
treatment of diabetes. As in all clinical deci-
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by value judgements, where the beneﬁts
oftreatmentareweighedagainstrisksand
costs in a subjective fashion. While we
realize that others may have different
judgements, we believe that the recom-
mendations made in this new iteration of
our treatment algorithm will guide ther-
apy and result in improved glycemic con-
trol and health status over time.
Glycemic goals of therapy
Controlled clinical trials, such as the Dia-
betes Control and Complications Trial
(DCCT) (4) and the Stockholm Diabetes
Study in type 1 diabetes (5) and the UK
Prospective Diabetes Study (UKPDS)
(6,7) and Kumamoto study (8) in type 2
diabetes, have helped to establish the gly-
cemic goals of therapy that result in im-
proved long-term outcomes. The clinical
trials, in concert with epidemiological
data (18,19), support decreasing glyce-
mia as an effective means of reducing
long-termmicrovascularandneuropathic
complications. The most appropriate tar-
get levels for blood glucose, on a day-to-
daybasis,andA1C,asanindexofchronic
glycemia, have not been systematically
studied.However,boththeDCCT(4)and
the UKPDS (6,7) had as their goals the
achievement of glycemic levels in the
nondiabeticrange.Neitherstudywasable
to maintain A1C levels in the nondiabetic
range in their intensive treatment groups,
achieving mean levels over time of 7%,
which is 4 SDs above the nondiabetic
mean.
Themostrecentglycemicgoalrecom-
mended by the American Diabetes Asso-
ciation, selected on the basis of
practicality and the projected reduction
in complications over time, is, in general,
anA1Clevelof7%(1).Themostrecent
glycemic goal set by the International Di-
abetes Federation is an A1C level of
6.5%. The upper limit of the nondia-
betic range is 6.1% (mean  SD. A1C
level of 5  2%) with the DCCT/UKPDS-
standardized assay, which has been pro-
mulgated through the National
Glycohemoglobin Standardization Pro-
gram(NGSP)andadoptedbythevastma-
jority of commercially available assays
(20). Several recent clinical trials have
aimed for A1C levels 6.5% with a vari-
etyofinterventions(11,12).Theresultsof
theActiontoControlCardiovascularRisk
in Diabetes (ACCORD) study, which had
the primary objective of decreasing CVD
with interventions aimed at achieving an
A1C level of 6.0% vs. interventions
aimed at achieving an A1C level of
7.9%, showed excess CVD mortality in
the intensive treatment group (11). Re-
sultsfromtheActioninDiabetesandVas-
cular Disease: Preterax and Diamicron
MR Controlled Evaluation (ADVANCE)
trial and the Veterans Affairs Diabetes
Trial, both of which had different inter-
ventions and study populations than
ACCORD, did not demonstrate any ex-
cess total or CVD mortality with intensive
regimens that achieved A1C levels com-
parable with the 6.5% in ACCORD
(12,13).However,noneofthestudieshas
demonstrated a beneﬁt of intensive glyce-
mic control on their primary CVD out-
comes.OurconsensusisthatanA1Clevel
of 7% should serve as a call to action to
initiate or change therapy with the goal of
achieving an A1C level of 7%. We are
mindful that this goal is not appropriate
orpracticalforsomepatients,andclinical
judgementbasedonthepotentialbeneﬁts
and risks of a more intensiﬁed regimen
needstobeappliedforeverypatient.Fac-
tors such as life expectancy, risk of hypo-
glycemia, and the presence of CVD need
to be considered for every patient before
intensifying the therapeutic regimen.
Assiduous attention to abnormalities
other than hyperglycemia that accom-
pany type 2 diabetes, such as hyperten-
sion and dyslipidaemia, has been shown
to improve microvascular and cardiovas-
cular complications. Readers are referred
topublishedguidelinesforadiscussionof
the rationale and goals of therapy for the
nonglycemic risk factors, as well as rec-




Our choice of speciﬁc antihyperglycemic
agents is predicated on their effectiveness
in lowering glucose, extraglycemic effects
that may reduce long-term complica-
tions, safety proﬁles, tolerability, ease of
use, and expense.
Effectiveness in lowering glycaemia
Except for their differential effects on gly-
cemia, there are insufﬁcient data at this
time to support a recommendation of one
class of glucose-lowering agents, or one
combination of medications, over others
withregardtoeffectsoncomplications.In
other words, the salutary effects of ther-
apyonlong-termcomplicationsappearto
be predicated predominantly on the level
of glycemic control achieved rather than
on any other speciﬁc attributes of the in-
tervention(s) used to achieve glycemic
goals.TheUKPDScomparedthreeclasses
of glucose-lowering medications (sulfo-
nylurea, metformin, or insulin) but was
unabletodemonstrateclearsuperiorityof
any one drug over the others with regard
todiabetescomplications(6,7).However,
the different classes do have variable ef-
fectiveness in decreasing glycemic levels
(Table 1), and the overarching principle
in selecting a particular intervention will
be its ability to achieve and maintain gly-
cemic goals. In addition to their inten-
tion-to-treat analyses demonstrating the
superiority of intensive versus conven-
tional interventions, the DCCT and
UKPDS demonstrated a strong correla-
tion between mean A1C levels over time
and the development and progression of
retinopathy and nephropathy (23,24).
Therefore, we think it is reasonable to
judge and compare blood glucose–
lowering medications, as well as combi-
nations of such agents, primarily on the
basis of their capacity to decrease and
maintain A1C levels and according to
their safety, speciﬁc side effects, tolerabil-
ity, ease of use, and expense.
Nonglycemic effects of medications
In addition to variable effects on glyce-
mia, speciﬁc effects of individual thera-
pies on CVD risk factors, such as
hypertension or dyslipidemia, were also
considered important. We also included
the effects of interventions that may ben-
eﬁt or worsen the prospects for long-term
glycemic control in our recommenda-
tions. Examples of these would be
changes in body mass, insulin resistance,
or insulin secretory capacity in type 2 di-
abetic patients.
Choosing speciﬁc diabetes
interventions and their roles in
treating type 2 diabetes
Numerous reviews have focused on the
characteristics of the speciﬁc diabetes in-
terventionslistedbelow(25–34).Inaddi-
tion, meta-analyses and reviews have
summarized and compared the glucose-
lowering effectiveness and other charac-
teristics of the medications (35–37). The
aim here is to provide enough informa-
tion to justify the choices of medications,
the order in which they are recom-
mended, and the use of combinations of
therapies. Unfortunately, there is a dearth
of high-quality studies that provide head-
to-head comparisons of the ability of the
medications to achieve the currently rec-
ommended glycemic levels. The authors
Consensus Statement
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conducted. However, even in the absence
of rigorous, comprehensive studies that
directly compare the efﬁcacy of all avail-
able glucose-lowering treatments and
their combinations, we feel that there are
enough data regarding the characteristics
of the individual interventions to provide
the guidelines below.
An important intervention that is
likely to improve the probability that a
patient will have better long-term control
of diabetes is to make the diagnosis early,
when the metabolic abnormalities of dia-
betes are usually less severe. Lower levels
of glycemia at the time of initial therapy
are associated with lower A1C levels over
time and decreased long-term complica-
tions (38).
Lifestyle interventions
The major environmental factors that in-
crease the risk of type 2 diabetes are over-
nutrition and a sedentary lifestyle, with
consequent overweight and obesity
(39,40). Not surprisingly, interventions
that reverse or improve these factors have
been demonstrated to have a beneﬁcial
effect on control of glycemia in estab-
lished type 2 diabetes (41). Unfortu-
nately, the high rate of weight regain has
limited the role of lifestyle interventions
as an effective means of controlling glyce-
mia in the long term. The most convinc-
ing long-term data indicating that weight
loss effectively lowers glycemia have been
generated in the follow-up of type 2 dia-
betic patients who have had bariatric sur-
gery. In this setting, with a mean
sustained weight loss of 20 kg, diabetes
is virtually eliminated (42–45). In addi-
tion to the beneﬁcial effects of weight loss
on glycemia, weight loss and exercise im-
prove coincident CVD risk factors, such
as blood pressure and atherogenic lipid
proﬁles, and ameliorate other conse-
quences of obesity (41,46,47). There are
few adverse consequences of such life-




monotherapy (%) Advantages Disadvantages
Tier 1: well-validated core
Step 1: initial therapy
Lifestyle to decrease weight and
increase activity 1.0–2.0 Broad beneﬁts Insufﬁcient for most within
ﬁrst year
Metformin 1.0–2.0 Weight neutral GI side effects, contraindicated
with renal insufﬁciency
Step 2: additional therapy
Insulin 1.5–3.5 No dose limit, rapidly effective,
improved lipid proﬁle








Tier 2: less well validated
TZDs 0.5–1.4 Improved lipid proﬁle
(pioglitazone), potential
decrease in MI (pioglitazone)




GLP-1 agonist 0.5–1.0 Weight loss Two injections daily, frequent




-Glucosidase inhibitor 0.5–0.8 Weight neutral Frequent GI side effects, three
times/day dosing, expensive
Glinide 0.5–1.5
a Rapidly effective Weight gain, three times/day
dosing, hypoglycemia,
expensive
Pramlintide 0.5–1.0 Weight loss Three injections daily,
frequent GI side effects,
long-term safety not
established, expensive
DPP-4 inhibitor 0.5–0.8 Weight neutral Long-term safety not
established, expensive
aRepaglinide more effective in lowering A1C than nateglinide. CHF, congestive heart failure; GI, gastrointestinal; MI, myocardial infarction.
Nathan and Associates
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incorporating them into usual lifestyle
and sustaining them and the usually mi-
nor musculoskeletal injuries and poten-
tialproblemsassociatedwithneuropathy,
such as foot trauma and ulcers, that may
occurasaresultofincreasedactivity.The-
oretically, effective weight loss, with its
pleiotropic beneﬁts, safety proﬁle, and
lowcost,shouldbethemostcost-effective
means of controlling diabetes—if it could
be achieved and maintained over the long
term.
Given these beneﬁcial effects, which
areusuallyseenrapidly—withinweeksto
months—and often before there has been
substantial weight loss (47), a lifestyle in-
tervention program to promote weight
loss and increase activity levels should,
with rare exceptions, be included as part
ofdiabetesmanagement.Weightlossofas
little as 4 kg will often ameliorate hyper-
glycemia.However,thelimitedlong-term
success of lifestyle programs to maintain
glycemic goals in patients with type 2 di-
abetes suggests that the large majority of
patients will require the addition of med-
ications over the course of their diabetes.
Medications
The characteristics of currently available
glucose-lowering interventions, when
used as monotherapy, are summarized in
Table 1. The glucose-lowering effective-
nessofindividualtherapiesandcombina-
tions demonstrated in clinical trials is
predicated not only on the intrinsic char-
acteristics of the intervention but also on
the duration of diabetes, baseline glyce-
mia, previous therapy, and other factors.
Amajorfactorinselectingaclassofdrugs,
or a speciﬁc medication within a class, to
initiate therapy or when changing ther-
apy, is the ambient level of glycemic con-
trol. When levels of glycemia are high
(e.g., A1C 8.5%), classes with greater
and more rapid glucose-lowering effec-
tiveness,orpotentiallyearlierinitiationof
combination therapy, are recommended;
however, patients with recent-onset dia-
betes often respond adequately to less in-
tensive interventions than those with
longer-term disease (48). When glycemic
levels are closer to the target levels (e.g.,
A1C7.5%),medicationswithlesserpo-
tential to lower glycemia and/or a slower
onset of action may be considered.
Obviously, the choice of glycemic
goalsandthemedicationsusedtoachieve
them must be individualized for each pa-
tient, balancing the potential for lowering
A1C and anticipated long-term beneﬁt
with speciﬁc safety issues, as well as other
characteristicsofregimens,includingside
effects, tolerability, ease of use, long-term
adherence,expense,andthenonglycemic
effectsofthemedications.Type2diabetes
is a progressive disease characterized by
worseningglycemia;higherdosesandad-
ditional medications are required over
time if treatment goals are to be met.
Metformin. In most of the world, met-
formin is the only biguanide available. Its
major effect is to decrease hepatic glucose
output and lower fasting glycemia. Typi-
cally, metformin monotherapy will lower
A1C levels by 1.5 percentage points
(27,49).Itisgenerallywelltolerated,with
the most common adverse effects being
gastrointestinal. Metformin monotherapy
isnotusuallyaccompaniedbyhypoglyce-
mia and has been used safely, without
causing hypoglycemia, in patients with
prediabetic hyperglycemia (50). Met-
formin interferes with vitamin B12 ab-
sorption but is very rarely associated with
anemia (27). The major nonglycemic ef-
fect of metformin is either weight stability
or modest weight loss, in contrast with
many of the other blood glucose–
lowering medications. The UKPDS dem-
onstrated a beneﬁcial effect of metformin
therapy on CVD outcomes (7), which
needs to be conﬁrmed. Renal dysfunction
is considered a contraindication to met-
formin use because it may increase the
risk of lactic acidosis, an extremely rare
(less than 1 case per 100,000 treated pa-
tients) but potentially fatal complication
(51). However, recent studies have sug-
gested that metformin is safe unless the
estimatedglomerularﬁltrationratefallsto
30 ml/min (52).
Sulfonylureas. Sulfonylureas lower gly-
cemia by enhancing insulin secretion. In
termsofefﬁcacy,theyappeartobesimilar
to metformin, lowering A1C levels by
1.5 percentage points (26,49). The ma-
jor adverse side effect is hypoglycemia,
whichcanbeprolongedandlifethreaten-
ing, but such episodes, characterized by a
need for assistance, coma, or seizure, are
infrequent. However, severe episodes are
relatively more frequent in the elderly.
Chlorpropamide and glibenclamide
(known as glyburide in the U.S. and Can-
ada), are associated with a substantially
greater risk of hypoglycemia than other
second-generation sulfonylureas (glicla-
zide, glimepiride, glipizide, and their ex-
tended formulations), which are
preferable (Table 1) (53,54). In addition,
weight gain of 2 kg is common follow-
ing the initiation of sulfonylurea therapy.
Although the onset of the glucose-
lowering effect of sulfonylurea mono-
therapyisrelativelyrapidcomparedwith,
for example, the thiazolidinediones
(TZDs), maintenance of glycemic targets
over time is not as good as monotherapy
with a TZD or metformin (55). Sulfonyl-
ureatherapywasimplicatedasapotential
cause of increased CVD mortality in the
University Group Diabetes Program
(UGDP) study (56). Concerns raised by
the UGDP that sulfonylureas, as a drug
class, may increase CVD mortality in type
2 diabetes were not substantiated by the
UKPDS or ADVANCE study (6,12). The
glycemic beneﬁts of sulfonylureas are
nearly fully realized at half-maximal
doses, and higher doses should generally
be avoided.
Glinides. Like the sulfonylureas, the
glinides stimulate insulin secretion, al-
though they bind to a different site within
the sulfonylurea receptor (28). They have
a shorter circulating half-life than the sul-
fonylureas and must be administered
more frequently. Of the two glinides cur-
rently available in the U.S., repaglinide is
almost as effective as metformin or the
sulfonylureas, decreasing A1C levels by
1.5 percentage points. Nateglinide is
somewhat less effective in lowering A1C
than repaglinide when used as mono-
therapy or in combination therapy
(57,58). The risk of weight gain is similar
tothatforthesulfonylureas,buthypogly-




dase inhibitors reduce the rate of diges-
tion of polysaccharides in the proximal
small intestine, primarily lowering post-
prandial glucose levels without causing
hypoglycemia. They are less effective in
lowering glycemia than metformin or the
sulfonylureas, reducing A1C levels by
0.5–0.8 percentage points (29). Since
carbohydrate is absorbed more distally,
malabsorption and weight loss do not oc-
cur;however,increaseddeliveryofcarbo-
hydrate to the colon commonly results in
increasedgasproductionandgastrointes-
tinalsymptoms.Inclinicaltrials,25–45%
of participants have discontinued -glu-
cosidase inhibitor use as a result of this
side effect (29,60).
Oneclinicaltrialexaminingacarboseas
a means of preventing the development of
diabetes in high-risk individuals with im-
paired glucose tolerance showed an unex-
pected reduction in severe CVD outcomes
Consensus Statement
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inhibitors needs to be conﬁrmed.
Thiazolidinediones. Thiazolidinedio-
nes (TZDs or glitazones) are peroxisome
proliferator–activatedreceptormodula-
tors; they increase the sensitivity of mus-
cle, fat, and liver to endogenous and
exogenous insulin (“insulin sensitizers”)
(31). The data regarding the blood glu-
cose–lowering effectiveness of TZDs
when used as monotherapy have dem-
onstrated a 0.5–1.4 percentage point
decrease in A1C. The TZDs appear to
have a more durable effect on glycemic
control, particularly compared with
sulfonylureas (55). The most common
adverse effects with TZDs are weight
gainandﬂuidretention,withperipheral
edema and a twofold increased risk for
congestive heart failure (61,62). There
is an increase in adiposity, largely sub-
cutaneous, with some reduction in vis-
ceral fat shown in some studies. The
TZDs either have a beneﬁcial (pioglita-
zone) or neutral (rosiglitazone) effect
on atherogenic lipid proﬁles (63,64).
Several meta-analyses have suggested a
30–40% relative increase in risk for
myocardialinfarction(65,66)withrosi-
glitazone. On the other hand, the Pro-
spective Pioglitazone Clinical Trial in
macrovascularevents(PROactive)dem-
onstrated no signiﬁcant effects of pio-
glitazonecomparedwithplaceboonthe
primary CVD outcome (a composite of
all-cause mortality, nonfatal and silent
myocardial infarction, stroke, major leg
amputation, acute coronary syndrome,
coronary artery bypass graft or percuta-
neous coronary intervention, and leg re-
vascularization) after 3 years of follow-up
(67). Pioglitazone was associated with a
16% reduction in death, myocardial in-
farction, and stroke—a controversial sec-
ondary end point reported to have
marginal statistical signiﬁcance (67).
Meta-analyses have supported a possible
beneﬁcial effect of pioglitazone on CVD
risk (68). Although the data are less than
conclusive for a CVD risk with rosiglita-
zone or a CVD beneﬁt with pioglitazone,
we have previously advised (69) caution
in using either TZD on the basis that they
arebothassociatedwithincreasedrisksof
ﬂuid retention and congestive heart fail-
ure and an increased incidence of frac-
tures in women and perhaps in men
(55,61,62,70). Although the meta-
analyses discussed above are not conclu-
sive regarding the potential cardiovascular
risk associated with rosiglitazone, given
that other options are now recom-
mended, the consensus group members
unanimously advised against using rosi-
glitazone. Currently, in the U.S., the
TZDs are approved for use in combina-
tion with metformin, sulfonylureas,
glinides, and insulin.
Insulin. Insulin is the oldest of the cur-
rently available medications and, there-
fore, the treatment with which we have
the most clinical experience. It is also the
most effective at lowering glycemia. Insu-
lin can, when used in adequate doses, de-
crease any level of elevated A1C to, or
close to, the therapeutic goal. Unlike the
other blood glucose–lowering medica-
tions, there is no maximum dose of insu-
lin beyond which a therapeutic effect will
notoccur.Relativelylargedosesofinsulin
(1 unit/kg), compared with those re-
quired to treat type 1 diabetes, may be
necessary to overcome the insulin resis-
tance of type 2 diabetes and lower A1C to
thetargetlevel.Althoughinitialtherapyis
aimed at increasing basal insulin supply,
usuallywithintermediate-orlong-acting-
insulins, patients may also require pran-
dial therapy with short- or rapid-acting
insulins (Fig. 1). The very rapid-acting
and long-acting insulin analogues have
not been shown to lower A1C levels more
effectively than the older, rapid-acting or
intermediate-acting formulations (71–
73). Insulin therapy has beneﬁcial effects
on triacylglycerol and HDL cholesterol
levels, especially in patients with poor
glycemic control (74), but is associated
with weight gain of 2–4 kg, which is
probablyproportionaltothecorrectionof
glycemia and predominantly the result of
the reduction of glycosuria. Insulin ther-
apy is also associated with hypoglycemia,
albeit much less frequently than in type 1
diabetes.Inclinicaltrialsaimedatnormo-
glycemia and achieving a mean A1C of
7%, severe hypoglycemic episodes (de-
ﬁned as requiring help from another per-
son to treat) occurred at a rate of between
one and three per 100 patient-years
(8,75–77),comparedwith61per100pa-
tient-years in the DCCT intensive therapy
group (4). Insulin analogues with longer,
nonpeaking proﬁles decrease the risk of
hypoglycemia modestly compared with
NPH, and analogues with very short du-
rations of action reduce the risk of hypo-
glycemia compared with regular insulin
(76,77).
Glucagon-like peptide-1 agonists (ex-
enatide). Glucagon-like peptide-1
(GLP-1) 7–37, a naturally occurring pep-
tide produced by the L-cells of the small
intestine, potentiates glucose-stimulated
insulin secretion. Exendin-4 has homol-
ogy with the human GLP-1 sequence but
has a longer circulating half-life. It binds
avidly to the GLP-1 receptor on the pan-
creatic -cell and augments glucose-
mediatedinsulinsecretion(32).Synthetic
exendin-4 (exenatide) was approved for
use in the U.S. in 2005 and is adminis-
tered twice per day by subcutaneous in-
jection. Although there are less published
data on this new compound than the
other blood glucose–lowering medica-
tions, exendin-4 appears to lower A1C
levels by 0.5–1 percentage points, mainly
by lowering postprandial blood glucose
levels(78–81).Exenatidealsosuppresses
glucagon secretion and slows gastric mo-
tility. It is not associated with hypoglyce-
mia but causes a relatively high frequency
ofgastrointestinaldisturbances,with30–
45% of treated patients experiencing one
or more episodes of nausea, vomiting, or
diarrhea (78–81). These side effects tend
to abate over time. In published trials, ex-
enatide is associated with weight loss of
2–3 kg over 6 months, some of which
may be a result of its gastrointestinal side
effects. Recent reports have suggested a
risk for pancreatitis associated with use of
GLP agonists; however, the number of
cases is very small and whether the rela-
tionship is causal or coincidental is not
clear at this time. Currently, exenatide
is approved for use in the U.S. with sul-
fonylurea, metformin, and/or a TZD.
Several other GLP-1 agonists and for-
mulations are under development.
Amylin agonists (pramlintide). Pram-
lintideisasyntheticanalogueofthe-cell
hormone amylin. It is administered sub-
cutaneously before meals and slows gas-
tric emptying, inhibits glucagon
production in a glucose-dependent fash-
ion, and predominantly decreases post-
prandial glucose excursions (33). In
clinical studies, A1C has been decreased
by 0.5–0.7 percentage points (82). The
major clinical side effects of this drug are
gastrointestinal in nature. 30% of
treated participants in the clinical trials
have developed nausea, but this side ef-
fect tends to abate with time on therapy.
Weight loss associated with this medica-
tion is 1–1.5 kg over 6 months; as with
exenatide,someoftheweightlossmaybe
the result of gastrointestinal side effects.
Currently, pramlintide is approved for
use in the U.S. only as adjunctive therapy
with regular insulin or rapid-acting insu-
lin analogues.
Nathan and Associates
DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009 197Figure 1—Initiation and adjustment of insulin regimens. Insulin regimens should be designed taking lifestyle and meal schedule into account. The
algorithm can only provide basic guidelines for initiation and adjustment of insulin. See reference 90 for more detailed instructions.
aPremixed
insulins not recommended during adjustment of doses; however, they can be used conveniently, usually before breakfast and/or dinner, if proportion
of rapid- and intermediate-acting insulins is similar to the ﬁxed proportions available. bg, blood glucose.
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GLP-1 and glucose-dependent insulino-
tropic peptide (GIP), the main insulino-
tropic peptides of intestinal origin
(incretins), are rapidly degraded by
dipeptidylpeptidasefour(DPP-4).DPP-4
is a member of a family of cell membrane
proteins that are expressed in many tis-
sues,includingimmunecells(34).DPP-4
inhibitors are small molecules that en-
hance the effects of GLP-1 and GIP, in-
creasing glucose-mediated insulin
secretion and suppressing glucagon se-
cretion (83,84). The ﬁrst oral DPP-4 in-
hibitor, sitagliptin, was approved by the
Food and Drug Administration in Octo-
ber 2006 for use as monotherapy or in
combination with metformin or TZDs.
Another DPP-4 inhibitor, vildagliptin,
was approved in Europe in February
2008, and several other compounds are
under development. In clinical trials per-
formed to date, DPP-4 inhibitors lower
A1Clevels by 0.6–0.9 percentage points
and are weight neutral and relatively well
tolerated (83,84). They do not cause hy-
poglycemia when used as monotherapy.
A ﬁxed-dose combination pill with met-
formin is available. The potential for this
class of compounds to interfere with im-
mune function is of concern; an increase
in upper respiratory infections has been
reported (34).
How to initiate diabetes therapy and
advance interventions
Except in rare circumstances, such as dia-
betic ketoacidosis or patients who are ex-
tremely catabolic or hyperosmolar or who
are unable to hydrate themselves ade-
quately (see SPECIAL CONSIDERATIONS/PATIENTS
below), hospitalization is not required for
initiation or adjustment of therapy. The pa-
tient is the key player in the diabetes care
team and should be trained and empow-
ered to adjust medications with the guid-
ance of health care professionals to achieve
glycemic goals and to prevent and treat hy-
poglycemia. Many patients may be man-
aged effectively with monotherapy;
however, the progressive nature of the dis-
ease will require the use of combination
therapy in many, if not most, patients over
time, to achieve and maintain glycemia in
the target range.
Themeasuresofglycemiathatareini-
tially targeted on a day-to-day basis are
fasting and preprandial glucose levels.
Self-monitoring of blood glucose (SMBG)
is an important element in adjusting or
adding new interventions and, in partic-
ular, in titrating insulin doses. The need
for and number of required SMBG mea-
surements are not clear (85) and are de-
pendent on the medications used. Oral
glucose-loweringregimensthatdonotin-
clude sulfonylureas or glinides, and are
therefore not likely to cause hypoglyce-
mia, usually do not require SMBG (86).
However, SMBG may be used to deter-
mine whether therapeutic blood glucose
targets are being achieved and for adjust-
mentoftreatmentregimenswithoutrequir-
ing the patient to have laboratory-based
blood glucose testing. Insulin therapy re-
quires more frequent monitoring.
The levels of plasma or capillary glu-
cose (most meters that measure ﬁnger-
stick capillary samples are adjusted to
provide values equivalent to plasma glu-
cose) that should result in long-term gly-
cemia in the nondiabetic target range, as
measured by A1C, are fasting and pre-
prandial levels between 3.9 and 7.2
mmol/l (70 and 130 mg/dl). If A1C levels
remain above the desired target despite
preprandial levels that are in range, post-
prandiallevels,usuallymeasured90–120
min after a meal, may be checked. They
should be 10 mmol/l (180 mg/dl) to
achieve A1C levels in the target range.
Attempts to achieve target glycemic
levels with regimens including sulfonyl-
ureas or insulin may be associated with
modesthypoglycemia,withglucoselevels
in the 3.1–3.9 mmol/l (55–70 mg/dl)
range. These episodes are generally well
tolerated, easily treated with oral carbo-
hydrate such as glucose tablets or 120–
180 ml (4–6 oz) of juice or nondiet soda,
and rarely progress to more severe hypo-
glycemia, including loss of consciousness
or seizures.
Algorithm
The algorithm (Fig. 2) takes into account
the characteristics of the individual inter-
ventions, their synergies, and expense.
The goal is to achieve and maintain A1C
levels of 7% and to change interven-
tionsatasrapidapaceastitrationofmed-
icationsallowswhentargetglycemicgoals
are not being achieved. Mounting evi-
dencesuggeststhataggressiveloweringof
glycemia, especially with insulin therapy,
in newly diagnosed diabetes can result in
sustained remissions, i.e., normoglyce-
mia without need for glucose-lowering
medications (87,88). Type 2 diabetes is a
progressive disease (89), and patients
should be informed that they are likely to
require the addition of glucose-lowering
medications over time.
The amylin agonists, -glucosidase
inhibitors, glinides, and DPP-4 inhibitors
are not included in the two tiers of pre-
ferred agents in this algorithm, owing to
their lower or equivalent overall glucose-
lowering effectiveness compared with the
ﬁrst- and second-tier agents and/or to
their limited clinical data or relative ex-
pense (Table 1). However, they may be
appropriate choices in selected patients.
Tier 1: well-validated core therapies
These interventions represent the best es-
tablished and most effective and cost-
effective therapeutic strategy for achieving
the target glycemic goals. The tier one algo-
rithm is the preferred route of therapy for
most patients with type 2 diabetes.
Step 1: lifestyle intervention and met-
formin. Based on the numerous demon-
strated short- and long-term beneﬁts that
accrue when weight loss and increased
levels of activity are achieved and main-
tained, as well as the cost-effectiveness of
lifestyleinterventionswhentheysucceed,
TITRATION OF METFORMIN
1. Begin with low-dose metformin (500 mg) taken once or twice per day with
meals (breakfast and/or dinner) or 850 mg once per day.
2. After 5–7 days, if gastrointestinal side effects have not occurred, advance dose
to 850, or two 500 mg tablets, twice per day (medication to be taken before
breakfast and/or dinner).
3. If gastrointestinal side effects appear as doses advanced, decrease to previous
lower dose and try to advance the dose at a later time.
4. The maximum effective dose can be up to 1,000 mg twice per day but is often
850 mg twice per day. Modestly greater effectiveness has been observed with
doses up to about 2,500 mg/day. Gastrointestinal side effects may limit the dose
that can be used.
5. Based on cost considerations, generic metformin is the ﬁrst choice of therapy.
A longer-acting formulation is available in some countries and can be given once
per day.
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tionsshouldbeinitiatedastheﬁrststepin
treating new-onset type 2 diabetes (Fig.
2). These interventions should be imple-
mented by health care professionals with
appropriate training—usually registered
dietitiansexperiencedinbehavioralmod-
iﬁcation—and be sensitive to ethnic and
cultural differences among populations.
Moreover, lifestyle interventions to im-
prove glucose, blood pressure, and lipid
levels, and to promote weight loss or at
least avoid weight gain, should remain an
underlying theme throughout the man-
agement of type 2 diabetes, even after
medications are used. For the 10–20% of
patients with type 2 diabetes who are not
obese or overweight, modiﬁcation of di-
etary composition and activity levels may
play a supporting role, but medications
are still generally required early in the
course of diabetes (see SPECIAL CONSIDER-
ATIONS/PATIENTS below).
The authors recognize that for most
individuals with type 2 diabetes, lifestyle
interventions fail to achieve or maintain
the metabolic goals either because of fail-
uretoloseweight,weightregain,progres-
sive disease, or a combination of factors.
Therefore, our consensus is that met-
formin therapy should be initiated con-
currently with lifestyle intervention at
diagnosis. Metformin is recommended as
theinitialpharmacologicaltherapy,inthe
absence of speciﬁc contraindications, for
its effect on glycemia, absence of weight
gain or hypoglycemia, generally low level
of side effects, high level of acceptance,
and relatively low cost. Metformin treat-
ment should be titrated to its maximally
effective dose over 1–2 months, as toler-
ated (see text box, entitled Titration of
Metformin). Rapid addition of other glu-
cose-lowering medications should be
considered in the setting of persistent
symptomatic hyperglycemia.
Step 2: addition of a second medica-
tion. If lifestyle intervention and the
maximal tolerated dose of metformin fail
to achieve or sustain the glycemic goals,
another medication should be added
within 2–3 months of the initiation of
therapy or at any time when the target
A1C level is not achieved. Another medi-
cation may also be necessary if metformin
is contraindicated or not tolerated. The
consensus regarding the second medica-
tion added to metformin was to choose
eitherinsulinorasulfonylurea(Fig.2).As
discussed above, the A1C level will deter-
mine in part which agent is selected next,
with consideration given to the more ef-
fective glycemia-lowering agent, insulin,
for patients with an A1C level of 8.5%
or with symptoms secondary to ehyper-
glycemia. Insulin can be initiated with a
basal (intermediate- or long-acting) insu-
lin (see Fig. 1 for suggested initial insulin
regimens)(90).However,manynewlydi-
agnosed type 2 diabetic patients will usu-
ally respond to oral medications, even if
symptoms of ehyperglycemia are present
(48).
Step 3: further adjustments. If lifestyle,
metformin, and sulfonylurea or basal in-
sulin do not result in achievement of tar-
get glycemia, the next step should be to
start,orintensify,insulintherapy(Fig.1).
Intensiﬁcation of insulin therapy usually
consists of additional injections that
might include a short- or rapid-acting in-
sulin given before selected meals to re-
duce postprandial glucose excursions
(Fig. 1). When insulin injections are
started, insulin secretagogues (sulfonyl-
urea or glinides) should be discontinued,
or tapered and then discontinued, since
they are not considered to be synergistic.
Although addition of a third oral agent
can be considered, especially if the A1C
level is close to target (A1C 8.0%), this
approach is usually not preferred, as it is
no more effective in lowering glycemia,
and is more costly, than initiating or in-
tensifying insulin (91).
Tier 2: less well-validated therapies
In selected clinical settings, this second-
tier algorithm may be considered. Specif-
ically, when hypoglycemia is particularly
undesirable (e.g., in patients who have
hazardousjobs),theadditionofexenatide
or pioglitazone may be considered. Rosi-
glitazone is not recommended. If promo-
tion of weight loss is a major consideration
andtheA1Clevelisclosetotarget(8.0%),
exenatideisanoption.Iftheseinterventions
are not effective in achieving target A1C, or
are not tolerated, addition of a sulfonylurea
could be considered. Alternatively, the tier
two interventions should be stopped and
basal insulin started.
Rationale for selecting speciﬁc
combinations
More than one medication will be neces-
saryforthemajorityofpatientsovertime.
Selection of the individual agents should
be made on the basis of their glucose-
lowering effectiveness and other charac-
teristics listed in Table 1. However, when
adding second antihyperglycemic medi-
cations, the synergy of particular combi-
nations and other interactions should be
considered. In general, antihyperglyce-
mic drugs with different mechanisms of
action will have the greatest synergy. In-
sulinplusmetformin(92)isaparticularly
effective means of lowering glycemia
while limiting weight gain.
Figure 2—Algorithm for the metabolic management of type 2 diabetes; Reinforce lifestyle inter-
ventions at every visit and check A1C every 3 months until A1C is 7% and then at least every 6
months. The interventions should be changed if A1C is 7%.
aSulfonylureas other than glyben-
clamide (glyburide) or chlorpropamide.
bInsufﬁcient clinical use to be conﬁdent regarding safety.
See text box, entitled TITRATION OF METFORMIN. See Fig. 1 for initiation and adjustment of insulin.
CHF, congestive heart failure.
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In the setting of severely uncontrolled di-
abetes with catabolism, deﬁned as fasting
plasmaglucoselevels13.9mmol/l(250
mg/dl), random glucose levels consis-
tently above 16.7 mmol/l (300 mg/dl),
A1C above 10%, or the presence of keto-
nuria, or as symptomatic diabetes with
polyuria, polydipsia and weight loss, in-
sulin therapy in combination with life-
style intervention is the treatment of
choice. Some patients with these charac-
teristics will have unrecognized type 1 di-
abetes; others will have type 2 diabetes
withsevereinsulindeﬁciency.Insulincan
be titrated rapidly and is associated with
the greatest likelihood of returning glu-
cose levels rapidly to target levels. After
symptoms are relieved and glucose levels
decreased, oral agents can often be added




consequences translate into enormous
human suffering and economic costs;
however, much of the morbidity associ-
ated with long-term microvascular and
neuropathic complications can be sub-
stantially reduced by interventions that
achieve glucose levels close to the nondi-
abetic range. Although new classes of
medicationsandnumerouscombinations
have been demonstrated to lower glyce-
mia, current-day management has failed
to achieve and maintain the glycemic lev-
els most likely to provide optimal health-
care status for people with diabetes.
Summary
The guidelines and treatment algorithm
presented here emphasize the following:
● Achievement and maintenance of near
normoglycaemia (A1C 7.0%)
● Initial therapy with lifestyle interven-
tion and metformin
● Rapid addition of medications, and
transitiontonewregimens,whentarget
glycemic goals are not achieved or sus-
tained
● Early addition of insulin therapy in pa-
tients who do not meet target goals
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